Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 2015

View Archived Issues

Cempra reports topline phase III data for intravenous solithromycin

Novel polymyxin derivatives show antibacterial activity

Sunshine Lake Pharma reports anti-HBV agents

Radiolabeled G-02113 may be useful for in vivo imaging of sst receptor-expressing tumors

PharmaCyte outlines plans for upcoming pancreatic cancer trial of Cell-in-a-Box + ifosfamide

Medifocus in license agreement with Duke for heat-activated and tumor-targeted immunotherapy

Alnylam describes a more potent RNAi agent targeting transthyretin for treating amyloidosis

Profiling of novel inhibitors of bacterial topoisomerases

Avalanche Biotechnologies reports 1-year follow up from phase I trial of rAAV.sFLT-1

Agios Pharmaceuticals provides pipeline update

Kowa files for approval of pemafibrate in Japan

Genocea reports topline results from phase IIa trial of universal Pneumococcal vaccine

Addyi launched in the U.S. for generalized hypoactive sexual desire disorder

Allergan completes acquisition of AqueSys

Novel JAK3 inhibitor shows promise for Th2-driven diseases

European Commission approves isavuconazole for invasive aspergillosis and mucormycosis

Roche discloses CB2 inverse agonists

Syros Pharmaceuticals patents CDK7 inhibitors

Instytut Farmaceutyczny reports antineoplastic agents

Calitor Sciences presents protein kinase inhibitors

Orion presents TRPA1 antagonists

Inotuzumab ozogamicin receives FDA breakthrough therapy designation for ALL

CFTR amplifiers enhance the effect of CFTR modulators

La Jolla Pharmaceutical starts phase I trial of hepcidin formulation LJPC-401

Avedro resubmits NDA for corneal cross-linking system

GenKyoTex's GKT-137831 granted U.S. orphan status for systemic sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...